Development of saliva-based cardiac troponin I point-of-care test using alpha-amylase depletion: a feasibility study.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
14
7
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
Cardiac troponin (cTn) is the biomarker of choice for detection of myocardial injury. There is a great need for simple point-of-care (POC) troponin testing among patients with chest pain, mainly in the prehospital setting. The purpose of this study was to evaluate the presence of cardiac troponin I (cTnI) in saliva of patients with myocardial injury using alpha-amylase depletion technique. Saliva samples were collected from 40 patients with myocardial injury who were tested positive for conventional high-sensitivity cardiac troponin T (cTnT) blood tests, and from 66 healthy volunteers. Saliva samples were treated for the removal of salivary alpha-amylase. Treated and untreated samples were tested with blood cTnI Rapid Diagnostic Test. Salivary cTnI levels were compared to blood cTnT levels. Thirty-six of 40 patients with positive blood cTnT had positive salivary samples for cTnI following alpha-amylase depletion treatment (90.00% sensitivity). Moreover, three of the four negative saliva samples were obtained from patients with relatively low blood cTnT levels of 100 ng/L or less (96.88% sensitivity for 100 ng/L and above). The negative predictive value was 93.65% and rose up to 98.33% considering the 100 ng/L cutoff. Positive predictive values were 83.72% and 81.58%, respectively. Among 66 healthy volunteers and 7 samples yielded positive results (89.39% specificity). In this preliminary work, the presence of cTnI in saliva was demonstrated for the first time to be feasibly identified by a POC oriented assay. The specific salivary alpha-amylase depletion technique was shown to be crucial for the suggested assay.
Identifiants
pubmed: 37335230
doi: 10.1097/MCA.0000000000001257
pii: 00019501-202308000-00008
doi:
Substances chimiques
Troponin I
0
Salivary alpha-Amylases
EC 3.2.1.1
Troponin T
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-355Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al.; ESC Scientific Document Group. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42:1289–1367.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al.; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40:237–269.
Neumann JT, Twerenbold R, Ojeda F, Sörensen NA, Chapman AR, Shah ASV, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med 2019; 380:2529–2540.
Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet 2018; 392:919–928.
Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med 2012; 125:1205–1213.
Eggers KM, Jernberg T, Lindhagen L, Lindahl B. High-sensitivity cardiac troponin T levels identify patients with non-ST-segment elevation acute coronary syndrome who benefit from invasive assessment. JACC Cardiovasc Interv 2018; 11:1665–1667.
Anand A, Shah ASV, Beshiri A, Jaffe AS, Mills NL. Global adoption of high-sensitivity cardiac troponins and the universal definition of myocardial infarction. Clin Chem 2019; 65:484–489.
Collinson PO, Saenger AK, Apple FS; IFCC C-CB. High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clin Chem Lab Med 2019; 57:623–632.
Sörensen NA, Neumann JT, Ojeda F, Giannitsis E, Spanuth E, Blankenberg S, et al. Diagnostic evaluation of a high-sensitivity troponin I point-of-care assay. Clin Chem 2019; 65:1592–1601.
Boeddinghaus J, Nestelberger T, Koechlin L, Wussler D, Lopez-Ayala P, Walter JE, et al.; APACE Investigators. Early diagnosis of myocardial infarction with point-of-care high-sensitivity cardiac troponin I. J Am Coll Cardiol 2020; 75:1111–1124.
Greabu M, Battino M, Mohora M, Totan A, Didilescu A, Spinu T, et al. Saliva—a diagnostic window to the body, both in health and in disease. J Med Life 2009; 2:124–132.
Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res 2010; 89:1016–1023.
Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DTW. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev 2013; 26:781–791.
Foley JD III, Sneed JD, Steinhubl SR, Kolasa JR, Ebersole JL, Lin Y, et al. Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114:616–623.
Mirzaii-Dizgah I, Riahi E. Salivary high-sensitivity cardiac troponin T levels in patients with acute myocardial infarction. Oral Dis 2013; 19:180–184.
Miller CS, Foley JD, Floriano PN, Christodoulides N, Ebersole JL, Campbell CL, et al. Utility of salivary biomarkers for demonstrating acute myocardial infarction. J Dent Res 2014; 93:72S–79S.
Bahbah EI, Noehammer C, Pulverer W, Jung M, Weinhaeusel A. Salivary biomarkers in cardiovascular disease: an insight into the current evidence. FEBS J 2021; 288:6392–6405. doi: 10.1111/febs.15689.
doi: 10.1111/febs.15689
Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, et al. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 2009; 55:1530–1538.
Gohel V, Jones JA, Wehler CJ. Salivary biomarkers and cardiovascular disease: a systematic review. Clin Chem Lab Med 2018; 56:1432–1442.
Vitorino R, Lobo MJ, Ferrer-Correira AJ, Dubin JR, Tomer KB, Domingues PM, et al. Identification of human whole saliva protein components using proteomics. Proteomics 2004; 4:1109–1115.
Hu S, Loo JA, Wong DT. Human saliva proteome analysis. Ann N Y Acad Sci 2007; 1098:323–329.
Hu S, Xie Y, Ramachandran P, Ogorzalek Loo RR, Li Y, Loo JA, et al. Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two-dimensional gel electrophoresis-mass spectrometry. Proteomics 2005; 5:1714–1728.
Deutsch O, Haviv Y, Krief G, Keshet N, Westreich R, Stemmer SM, et al. Possible proteomic biomarkers for the detection of pancreatic cancer in oral fluids. Sci Rep 2020; 10:1–13.
Xiao H, Zhang Y, Kim Y, Kim S, Kim JJ, Kim KM, et al. Differential proteomic analysis of human saliva using tandem mass tags quantification for gastric cancer detection. Sci Rep 2016; 6:1–13.
Huang H, Mackeen MM, Cook M, Oriero E, Locke E, Thézénas ML, et al. Proteomic identification of host and parasite biomarkers in saliva from patients with uncomplicated Plasmodium falciparum malaria. Malar J 2012; 11:1–9.
Deutsch O, Fleissig Y, Zaks B, Krief G, Aframian DJ, Palmon A. An approach to remove alpha amylase for proteomic analysis of low abundance biomarkers in human saliva. Electrophoresis 2008; 29:4150–4157.
Mak WC, Beni V, Turner APF. Lateral-flow technology: from visual to instrumental. TRAC Trends Anal Chem 2016; 79:297–305.
Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129–2138.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2009; 1:1066–1067.
Ebersole JL, Kryscio RJ, Campbell C, Kinane DF, McDevitt JT, Christodoulides N, et al. Serum and salivary cardiac analytes in acute myocardial infarction related to oral health status. Sens Technol Glob Health Mil Med Environ Monit IV 2014; 9112:91120G.
Mirzaii-Dizgah I, Riahi E. Salivary troponin I as an indicator of myocardial infarction. Indian J Med Res 2013; 138:861–865.